Haleon (XTER:H6D0) Gross-Profit-to-Asset % : 21.74% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Haleon's annualized Gross Profit for the quarter that ended in Mar. 2024 was €8,594 Mil. Haleon's average Total Assets over the quarter that ended in Mar. 2024 was €39,530 Mil. Therefore, Haleon's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 21.74%.

Haleon Gross-Profit-to-Asset % Historical Data

The historical data trend for Haleon's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Gross-Profit-to-Asset % Chart

Haleon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

13.45

16.36

17.90

18.77

19.69

Haleon Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									20.84	20.02	19.99	17.40	21.74

Competitive Comparison of Haleon's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Haleon's Gross-Profit-to-Asset % falls into.

Haleon Gross-Profit-to-Asset % Calculation

Haleon's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	7831.644	/	( (40030.889	+	39529.665)	/ 2 )
	=	7831.644	/	39780.277
	=	19.69 %

Haleon's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	8594.46	/	( (39529.665	+	0)	/ 1 )
	=	8594.46	/	39529.665
	=	21.74 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Haleon Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Haleon's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon (XTER:H6D0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (XTER:H6D0) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

HLNCF:USA HLN:USA HLN1:Mexico HLNl:UK HLN:UK

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

Haleon (XTER:H6D0) Headlines

No Headlines